Hypertrophic cardiomyopathy;Cardiomyopathie hypertrophique

EMC - Cardiologie-Angeiologie

Volumn 2, Issue 2, 2005, Pages 103-119

  Charron, P ^a   Komajda, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiomyopathy; Genetics; Heart failure; Hypertrophy; Sudden death

Indexed keywords

EID: 32644434119     PISSN: 17626137     EISSN: 17626137     Source Type: Journal    
DOI: 10.1016/j.emcaa.2005.01.003     Document Type: Short Survey

References (110)

1. Alfonso F, Nihoyannopoulos P, Stewart J, Dickie S, Lemery R, McKenna WJ. Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:965-71.
2. Betocchi S, Oscione F, Losi MA, Pace L, Boccalatte M, Perrone-Filardi P, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1996;78:451-7.
3. Bigelow WG, Trimble AS, Wigle ED, Adelman AG, Felderhof CH. The treatment of muscular subaortic stenosis. J Thorac Cardiovasc Surg 1974;68:384-92.
4. Bonnow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short and long term effects. Circulation 1985;72:853-64.
5. Brock R. Functional obstruction of the left ventricle. Guys Hosp Rep 1957;106:221-38.
6. Brunner-La Schonbeck MH, Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg 1998;65:1207-14.
7. Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population based study, 1976 through 1990. Circulation 1995;92: 2488-95.
8. Cannon RO, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation 1989;79:766-75.
9. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
10. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998;79:331-6.
11. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engt J Med 2003; 349:1027-35.
12. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Millaire A, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 1997; 96:214-9.
13. Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Richard P, et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Counsel 1997;8:107-14.
14. Charron P, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagege A, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J 1998;19:1377-82.
15. Charron P, Heron D, Gargiulo M, Richard P, Dubourg O, Desnos M, et al. Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience. J Med Genet 2002;39:741-6.
16. Charron P, Komajda M. Génétique des cardiomyopathies, Encyd Méd Chir (Elsevier SAS, Paris), Cardiologie, 11-023-B-20, 2003: 10p.
17. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. Circulation 1989;80:564-72.
18. Cooley DA, Leachman RD, Wukash DC. Diffuse muscular subaortic stenosis: surgical management. Am J Cardiol 1973;31:1-6.
19. Delahaye F. Les nouvelles recommandations sur la prophylaxie de l'endocardite infectieuse. Lettre Cardiol 2003; 362:22-5.
20. Dilsizian V, Bonow RO, Epstein SE, Fanapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
21. Dubourg O, Isnard R, Hagège A, Jondeau G, Desnos M, Sacrez A, et al. Doppler echocardiography in familial hypertrophic cardiomyopathy: the French cooperative study. Echocardiography 1995;12:235-40.
22. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4.
23. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-91.
24. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respects to intraprocedural myocardial contrast echocardiography. Circutation 1998;98:2415-21.
25. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-74.
26. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation 1992;86:730-40.
27. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-42.
28. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coll Cardiol 1987;9:288-94.
29. Frank MJ, Abdulla AM, Canedo MI, Saylors SE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 1978;42:993-1001.
30. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990;82:1995-2002.
31. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a β-cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006.
32. Geisterfer-Lowrance AAT, Christe M, Conner DA, Ingwall IS, Schoen FJ, Seidman CE, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996;272: 731-4.
33. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 2002;106:454-69.
34. Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 1987;58:259-66.
35. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class la antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstuctive cardiomyopathy. Circulation 1997;96:1520-4.
36. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980;62:1054-66.
37. Hess OM, Grimm J, Krayenbuehl HP. Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness. Eur Heart J 1983; 4(supplF):47-56.
38. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004;93:1192-4.
39. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dualchamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992;339:1318-23.
40. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al. Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997;18:1249-56.
41. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003;92:1183-6.
42. Kizilbash AM, Heinele SK, Grayburn PA. Spontaneous variability of leftventricular outflox tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998;97: 461-6.
43. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992;85:1651-60.
44. Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993;72:939-43.
45. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Non surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81.
46. Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodling of the coronary circulation. Circulation 1998;97:230-3.
47. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience. Z Kardiol 2000;89:559-64.
48. Van der Lee C, Kofflard MJ, Van Herwerden LA, Vletter WB, Ten Cate FJ. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation 2003;108:2088-92.
49. LeJemtel TH, Factor SM, Koenigsberg M, O'Reilly M, Frater R, Sonnenblick EH. Mural vegetations at the site of endocardial trauma in infective endocarditis complicating idiopathic hypertrophic subaortic stenosis. Am J Cardiol 1979;44:569-74.
50. Lemery R, Kleinebenne A, Nihoyannopoulos P, Aber V, Alfonso F, McKenna WJ. Q. waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol 1990; 16:368-74.
51. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in hypertrophic obstructive cardiomyopathy. PIC study group. Am J Cardiol 1999; 83:903-7.
52. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774-8.
53. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mot Cell Cardiol 2001;33: 655-70.
54. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24-hour electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48:252-7.
55. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
56. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94.
57. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982;65:7-16.
58. Maron BJ, Wolfson JK, Giro E, Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983;51:189-94.
59. Maron BJ, Nichols III PF, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984;53:1087-94.
60. Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation 1992;85(suppll):157-163.
61. Maron BJ, Isner JM, McKenna WJ. Task force 3. 26th Bethesda conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol 1994;24:880-5.
62. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Circulation 1995;92: 785-9.
63. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 1996;276:199-204.
64. Maron BJ, Hauser RG, Roberts WC. Hypertrophic cardiomyopathy with left ventricular apical diverticulum. Am J Cardiol 1996;77:1263-5.
65. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81:1339-44.
66. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-5.
67. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-33.
68. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102: 858-64.
69. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverterdefibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
70. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7.
71. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
72. Maron BJ, McKenna WJ, Danielson GK, Kappenberger U, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology: Clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 2003;24:1965-91.
73. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
74. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, et al. Working Groups of the American Heart Association. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109:2807-16.
75. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-71.
76. McKenna WJ, England D, Dienfield JE, Oakley C, Goodwin J. Arrythmia in hypertrophic cardiomyopathy. I. Influence on prognosis, Br Heart J 1981;46:168-72.
77. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia, Br Heart J 1985;53:412-6.
78. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE, Dickie S, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-53.
79. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9.
80. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis: techniques and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
81. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254-61.
82. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999;99:344-7.
83. Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003;108:395-8.
84. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR, Tajik AF. Effects of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute doppler echocardiography and catheterization hemodynamic study. J Am Coll Cardiol 1996;27:421-30.
85. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435-41.
86. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104: 2517-24.
87. Palka P, Lange A, Fleming A, Donnelly JE, Dutka DP, Starkey IR, et al. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol 1997;30:760-8.
88. Peliccia A, Maron BJ, Spataro A, Proshan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324:295-301.
89. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-5.
90. Primo J, Geelen P, Brugada J, Lorga Filho A, Mont L, Wellens F, et al. Hypertrophic Cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31:1081-5.
91. Report of the 1995 World Health Organisation / International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2.
92. Rosing DR, Idanpaan-Heikkila U, Maron BJ, Bonow RO, Epstein SE. Use of calcium channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985;55(ssuppl): 185B-195B.
93. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessement of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91.
94. Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, et al. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1978;58:402-8.
95. Shamim W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Flather M, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326-33.
96. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988:62:1085-8.
97. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurence and significance of progressive left ventricular thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;59:123-9.
98. Spirito P, Chiarella F, Carratino L, Berisso MZ, Belloti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989:320:749-55.
99. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15: 808-13.
100. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997:336:775-85.
101. Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR, et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999;99:2132-7.
102. Teare D. Asymetrical hypertrophy of the heart in young adults. Br Heart J 1958;21:1-8.
103. Thomson HL, Morris-Thurgood J, Atherton J, Frenneaux M. Reduced cardiopulmonary baroreflex sensitivity in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;31:1377-82.
104. Topol EJ, Traill TA, Fortuin N. Hypertensive hypertrophic cardiomyopathy in the elderly. N Engl J Med 1985;312: 277-83.
105. Vulpian A. Contribution à l'étude des rétré cissements de l'orifice ventriculo-aortique. Arch Physiol 1868;3:456-7.
106. Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy: relations to clinical presentation and outcome. Eur Heart J 1998;19:500-7.
107. Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F, et al. Hypertrophic non obstructive cardlomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardlographic features in 30 patients. Am J Cardiol 1979;44:401-12.
108. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy: a risk factor for sudden death. N Engl J Med 1998;339:1201-9.
109. Zhu DW, Sun H, Hill R, Roberts R. The value of electro-physiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21:299-302.
110. Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8 080 adults. Am J Med 2004;116:14-8.